Background
A noninvasive method for evaluating renal blood flow (RBF) in patients with chronic kidney disease (CKD) may have clinical value in disease staging, management, and prognostication.
Purpose
To evaluate effectiveness of three‐dimensional pseudocontinuous arterial spin labeling (pCASL) and pulsed arterial spin labeling (PASL) in assessment of cortex and outer medulla (cortex/OM) RBF in CKD patients and healthy volunteers (HVs).
Study Type
Prospective, in a single institution.
Subjects
A total of 48 CKD patients (stage 1, 2, 3, and 4–5: N = 11, 12, 13, and 12, respectively) and 18 HVs
Field Strength/Sequence
3 T, pCASL, and PASL with a three‐dimensional hybrid gradient echo/spin echo sequence.
Assessment
Quality of RBF images derived from pCASL and PASL were evaluated and RBF in cortex/OM measured. Clinical and laboratory data were recorded.
Statistical Tests
Image quality differences between pCASL and PASL were evaluated with Wilcoxon signed‐rank test. For both methods, analysis of variance, followed by Fisher's LSD‐t test, was used to determine whether RBF differed between CKD stages and HVs. Pearson correlation coefficients were calculated to assess strength of relationships between cortex/OM RBF and data from clinical and laboratory tests.
Results
Image quality differences were significantly higher in pCASL than PASL in both patients and HVs (both P < 0.05). For pCASL, cortex/OM RBF of patients were significantly lower than those of HVs (P < 0.05). Cortex/OM RBF were higher in S1 and S2 patients than those in S3 and S4–5 (P < 0.05). For PASL, only RBF in cortex of S1 and S2 patients were significantly higher than those of S4–5 (P < 0.05). Good correlations between pCASL RBF and estimated glomerular filtration (eGFR) were found in cortex/OM of patients (rho = 0.796 and 0.798, respectively, both P < 0.05), higher than those between PASL RBF and eGFR (rho = 0.430 and 0.374, respectively, both P < 0.05).
Data Conclusion
Three‐dimensional pCASL may potentially be a noninvasive technique to assess renal perfusion in CKD patients in different stages.
Level of Evidence
1
Technical Efficacy
Stage 2